Form 4: Director Merilee Raines Receives Equity Grant at OCUL

Ocular Therapeutix director Merilee Raines was granted 14,000 restricted stock units and 44,000 stock options.

Summary

• Director Merilee Raines received a grant of 14,000 restricted stock units (RSUs) on June 10, 2026.
• The director was also granted 44,000 stock options with an exercise price of $8.74 per share.
• Both the RSUs and stock options are subject to a one-year vesting schedule, contingent upon continued service on the board of directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant market-moving information.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard retention incentive for board members.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Vesting is contingent upon continued service on the board of directors.

Future Outlook

The equity grants vest on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, whichever is earlier.

Management Comments

• The grants were issued under the 2021 Stock Incentive Plan, as amended.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The use of a one-year cliff vesting period for director equity is consistent with standard practices for mid-cap biotechnology companies.

Corporate Governance

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of equity grants on June 10, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

OCUL, Ocular Therapeutix, Form 4, Insider Trading, Equity Compensation, Director Compensation